The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | CHEP-BV followed by BV consolidation in CD30-expressing PTCL
Alex Herrera, MD, City of Hope, Duarte, CA, provides an update on the multicenter Phase II trial (NCT03113500) evaluating the safety and efficacy of adding etoposide to brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with newly diagnosed CD30-expressing peripheral T-cell lymphomas (PTCL). CHEP-BV followed by BV consolidation was tolerable and effective, especially when CHEP-BV was given followed by an autologous stem cell transplant (ASCT) and BV consolidation performed after ASCT. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
